ojemda - tovorafenib
(Tovorafenib)Day One Biopharmaceuticals, Inc.
Usage: Ojemda treats relapsed or refractory pediatric low-grade glioma (LGG) in patients 6 months and older with a BRAF fusion, rearrangement, or V600 mutation. Approved under accelerated approval based on response rate.